Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OMP-54F28, Paclitaxel and Carboplatin · 1 trial · 1 indication
The maximum tolerated dose (MTD) will be determined in patients treated with OMP-54F28/paclitaxel/carboplatin (from Day 0 - 21)
| Arm | Type | Description |
|---|---|---|
| Drug: OMP-54F28, Paclitaxel and Carboplatin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| OMP-54F28, Paclitaxel and Carboplatin | DRUG | - |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥18 years * Histologically documented ovarian, primary peritoneal or fallopian tube cancer * Recurrent platinum-sensitive disease, defined as disease progression ≥6 months after completing a minimum of 4 cycles of a platinum-containing regime...
Top 20 of 59 competitors
OMP-54F28 is an investigational monoclonal antibody being studied for the treatment of solid tumors, including pancreatic cancer, ovarian cancer, and hepatocellular cancer. It is in Phase 1 clinical development and is not yet approved by the FDA.
OMP-54F28 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. It is being evaluated in oncology for its potential to treat various solid tumors.
OMP-54F28 is being developed by Mereo BioPharma Group plc, a biopharmaceutical company listed on the stock exchange under the ticker MREO.
OMP-54F28 is in Phase 1 clinical development. It has completed four Phase 1 trials, and no active trials are currently listed. It remains investigational and has not received FDA approval.
OMP-54F28 has completed four Phase 1 trials: NCT01608867 in solid tumors, NCT02050178 in pancreatic cancer, NCT02069145 in hepatocellular cancer, and NCT02092363 in ovarian cancer. All trials were completed in the United States.
OMP-54F28 is not known to have alternative names. It is a distinct investigational monoclonal antibody being developed by Mereo BioPharma for multiple oncology indications.